From Wikipedia, the free encyclopedia
Chemical compound
Clevudine
Routes of administration Oral
ATC code
1-[(2S ,3R ,4S ,5S )-3-fluoro-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine- 2,4-dione
CAS Number
PubChem
CID
ChemSpider
UNII
KEGG
ChEMBL
Formula C 10 H 13 F N 2 O 5
Molar mass 260.221 g·mol−1 3D model (
JSmol )
O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)[C@H]2F)CO
InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1
N Key:GBBJCSTXCAQSSJ-XQXXSGGOSA-N
N
N Y
(what is this?)
(verify)
Clevudine (
INN ) is an antiviral drug for the treatment of
hepatitis B (HBV). It is already approved for HBV in
South Korea and the
Philippines . It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir .
Researchers in South Korea are testing clevudine at lower doses in combination with
adefovir for continued use.
[2]
It is a
nucleoside analog .
[3]
References
^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008).
"ATC/DDD Classification (FINAL): New ATC 5th level codes" . WHO Collaborating Centre for Drug Statistics Methodology. Archived from
the original on 2008-05-06. Retrieved 2008-09-05 .
^ Tak WY, Yang JM, Kim BI, Baik SK, Cheon GJ, Byun KS, Kim DY, Yoo BC, et al. (May 2014).
"A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients" . Hepatology International . 8 (3): 375–381.
doi :
10.1007/s12072-014-9537-5 .
PMC
4116600 .
PMID
25101150 .
^ Lee HS, Chung YH, Lee K, et al. (May 2006).
"A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B" . Hepatology . 43 (5): 982–8.
doi :
10.1002/hep.21166 .
PMID
16628625 .